Add like
Add dislike
Add to saved papers

Genetic counseling of a prenatally detected familial 18.79-kb Xp21.1 microduplication encompassing exon 13 of DMD in a pregnancy with no apparent phenotypic abnormalities in the male carriers in the family.

OBJECTIVE: We present genetic counseling of a prenatally detected familial 18.79-kb Xp21.1 microduplication encompassing exon 13 of DMD in a pregnancy with no apparent phenotypic abnormalities in the male carriers in the family.

CASE REPORT: A 35-year-old, gravida 2, para 0, woman underwent amniocentesis at 17 weeks of gestation because of advanced maternal age. Amniocentesis revealed a karyotype of 46,XY. Simultaneous aCGH analysis on the DNA extracted from uncultured amniocytes revealed an 18.79-kb Xp21.1 microduplication, or arr Xp21.1 (32,608,400-32,627,193) × 2.0 [GRCh37 (hg19)] encompassing only exon 13 of the gene of DMD (31,137,345-33,357,706) [GRCh37 (hg19)]. Multiplex ligation-dependent probe amplification (MLPA) analysis of the family showed that the mother and her 32-year-old brother carried the same duplication but without apparent phenotypic abnormalities and no features of DMD. Prenatal ultrasound was normal. She was referred for genetic counseling at 24 weeks of gestation, and continuing pregnancy was advised. At 38 weeks of gestation, a 3530-g phenotypically normal male baby was delivered. aCGH analysis of the umbilical cord confirmed the result of arr Xp21.1 (32,608,400-32,627,193) × 2.0 [GRCh37 (hg19)] encompassing only exon 13 of the gene of DMD (31,137,345-33,357,706) [GRCh37 (hg19)].

CONCLUSION: Xp21.1 microduplication encompassing exon 13 of the DMD gene can be a benign genetic variant.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app